top of page


FDA grants full approval to Keytruda and Keytruda Qlex for TMB-high advanced solid tumours with updated biomarker threshold
The FDA has converted Keytruda's tumour-mutational-burden-high solid tumour indication to traditional approval, extending the authorisation to Keytruda Qlex and updating the biomarker threshold.

nuaxia
Oct 232 min read


Merck licenses SciBrunch KRAS G12D inhibitor in deal worth up to $2.13bn
Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.

nuaxia
Sep 292 min read


FDA approves Welireg plus Lenvima for advanced clear-cell renal cell carcinoma after immunotherapy
The FDA has approved Welireg in combination with Lenvima for adults with advanced clear-cell renal cell carcinoma following prior PD-1 or PD-L1 immunotherapy.

nuaxia
Sep 252 min read


Kelun’s Merck-Partnered ADC Delivers Phase III Win in First-Line PD-L1-Negative Lung Cancer
Sacituzumab tirumotecan plus Keytruda improves progression-free survival in advanced NSCLC, expanding potential role of ADC-immunotherapy combinations.

nuaxia
Jul 173 min read


Merck’s Lipfendra Becomes First FDA-Approved Oral PCSK9 Inhibitor for High Cholesterol
Oral cholesterol therapy offers an alternative to injectable PCSK9 inhibitors as Merck targets multi-billion-dollar cardiovascular market.

nuaxia
Jul 173 min read


Merck KGaA Expands Life Sciences Business with $11.3bn Bio-Techne Acquisition
Merck KGaA has agreed to acquire US-based life sciences company Bio-Techne, significantly expanding its presence across the life sciences value chain.

nuaxia
Jun 303 min read


Merck Expands AI Drug Discovery Push with $510m Protillion Partnership
Merck & Co. has strengthened its commitment to AI-driven drug discovery through a new multi-year partnership with Protillion Biosciences, signing a deal worth up to $510 million focused on identifying and engineering novel therapeutic candidates.

nuaxia
Jun 213 min read


FDA backs Merck’s dual-pronged push in kidney cancer with Welireg–Keytruda combo approval
The US Food and Drug Administration (FDA) has approved a combination regimen of Merck & Co.’s Keytruda (pembrolizumab) and Welireg (belzutifan).

nuaxia
Jun 152 min read


Merck’s $6.7B Terns Deal Shows Big Pharma Is Preparing for Patent Cliffs
Merck has agreed to acquire biotechnology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening its oncology pipeline ahead of the upcoming patent expiry of its blockbuster drug, Keytruda.

nuaxia
Mar 302 min read
bottom of page